SCHEMBL25868744

SCHEMBL25868744

CC(C)(C)OC(=O)N1CCN(CCCN2C(=O)c3ccc4c5cccc6c(Br)ccc(c7ccc(c3c47)C2=O)c65)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ PABPC1 P11940 1/20 0.45
▸ CYP1B1 Q16678 4/20 0.43
▸ HTR1A P08908 3/20 0.43
▸ BRD4 O60885 3/20 0.42
▸ CHRM2 P08172 1/20 0.42
▸ CHRM4 P08173 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ TERT O14746 3/20 0.41
▸ PARP1 P09874 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25868741 0.83 ALDH1A1 (0.55) MEN1KMT2APOLBKDM4ENPC1
SCHEMBL12413498 0.81 MEN1 (0.64) MEN1KMT2APOLBKDM4EALDH1A1
SCHEMBL30149981 0.81 CYP1B1 (0.52) MEN1KMT2APOLBKDM4ENPC1
SCHEMBL28942809 0.81 CYP1B1 (0.52) MEN1KMT2APOLBKDM4ENPC1
SCHEMBL29391217 0.80 DRD2 (0.56) MEN1KMT2AKDM4EALDH1A1HTR1A
SCHEMBL17844904 0.80 DRD2 (0.56) MEN1KMT2AKDM4EALDH1A1HTR1A
SCHEMBL29944565 0.78 ALDH1A1 (0.57) MEN1KMT2AKDM4EALDH1A1HTR1A
SCHEMBL829637 0.78 ALDH1A1 (0.57) MEN1KMT2AKDM4EALDH1A1HTR1A
SCHEMBL12263981 0.77 MAOB (0.57) MEN1KMT2AKDM4EALDH1A1HTR1A
SCHEMBL29263692 0.77 MAOB (0.57) MEN1KMT2AKDM4EALDH1A1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373929-A1 FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. (CN) 2023-11-23 — — US disclosed
US-20230373929-A1 FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. (CN) 2023-11-23 — — US disclosed
EP-4215521-A1 FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Xiangbei Welman Pharmaceutical Co., Ltd (CN) 2023-07-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373929-A1 FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF WEE1, CYP51A1, WEE2 MEN1 1023/4885KMT2A 2753/4885POLB 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback